Journal article
Molecules, 2020
Researcher
Researcher
Department of Chemical Science and Materials Technology (DSCTM)
National Research Council (CNR)
Istituto per lo Studio dei Materiali Nanostrutturati, CNR
Via U. La Malfa 153, 90146 Palermo (Italy)
Researcher
Department of Chemical Science and Materials Technology (DSCTM)
National Research Council (CNR)
Istituto per lo Studio dei Materiali Nanostrutturati, CNR
Via U. La Malfa 153, 90146 Palermo (Italy)
APA
Click to copy
Cascioferro, S., (co-first author), G. L. P., Parrino, B., Hassouni, B. E., Carbone, D., Arizza, V., … Diana, P. (2020). 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Molecules.
Chicago/Turabian
Click to copy
Cascioferro, S., G. Li Petri (co-first author), B. Parrino, B. El Hassouni, D. Carbone, V. Arizza, U.Perricone, et al. “3-(6-Phenylimidazo [2,1-b][1,3,4]Thiadiazol-2-Yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma.” Molecules (2020).
MLA
Click to copy
Cascioferro, S., et al. “3-(6-Phenylimidazo [2,1-b][1,3,4]Thiadiazol-2-Yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma.” Molecules, 2020.
BibTeX Click to copy
@article{s2020a,
title = {3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma},
year = {2020},
journal = {Molecules},
author = {Cascioferro, S. and (co-first author), G. Li Petri and Parrino, B. and Hassouni, B. El and Carbone, D. and Arizza, V. and U.Perricone and Padova, A. and Funel, N. and Peters, G. and Cirrincione, G. and Giovannetti, E. and Diana, P.}
}
A new series of imidazo[2,1-b][1,3,4]thiadiazole derivatives was efficiently synthesized and screened for their in vitro antiproliferative activity on a panel of pancreatic ductal adenocarcinoma (PDAC) cells, including SUIT-2, Capan-1 and Panc-1. Compounds 9c and 9l, showed relevant in vitro antiproliferative activity on all three pre-clinical models with half maximal inhibitory concentration (IC50) ranging from 5.11 to 10.8 µM, while the compounds 9e and 9n were active in at least one cell line. In addition, compound 9c significantly inhibited the migration rate of SUIT-2 and Capan-1 cells in the scratch wound-healing assay. In conclusion, our results will support further studies to increase the library of imidazo [2,1-b][1,3,4] thiadiazole derivatives for deeper understanding of the relationship between biological activity of the compounds and their structures in the development of new antitumor compounds against pancreatic diseases.